Medical research and AI platform OpenEvidence has raised $210 million in a Series B funding round, co-led by Google Ventures and Kleiner Perkins. The investment also included participation from Sequoia Capital, Coatue, Conviction and Thrive, bringing the company’s total funding to over $300 million.
According to the announcement, OpenEvidence gives clinicians instant access to evidence-based medical insights by drawing from peer-reviewed literature in leading journals such as The New England Journal of Medicine and JAMA, eliminating the delays and inefficiencies of traditional medical databases. The platform is used by more than 10,000 hospitals and medical centers nationwide.
Daniel Nadler, founder of OpenEvidence, shared the following in a statement: “At a time when U.S. healthcare faces the dual challenges of clinician burnout and a projected physician shortfall of nearly 100,000 by 2030, the question of AI’s role in bridging the gap is paramount. When physicians’ lives are hard, patients’ lives are harder. OpenEvidence’s commitment to building an AI copilot for clinicians is rooted in the belief that AI will be a force for good in the world, ultimately benefiting both healthcare professionals and the patients they serve.”
In addition to the funding news, the company also announced the launch of OpenEvidence DeepConsult, an AI agent built for physicians that can autonomously conduct medical research, even when the physician is not present.
